Unless you have been living under a rock, you no doubt have noticed that drug price increases have resulted in a wave of public criticism, playing right into the media’s demonization of the pharmaceutical industry, and even becoming an election year issue. The United States is one of the only developed nations that largely does not restrict the drug prices charged to the public or government. This has led some in the industry to be complacent about the public perception of drug price increases.
While pharmaceutical companies should be able to price their products at whatever level they determine is appropriate without government intervention, the industry would benefit by getting ahead of government regulation and public backlash. The old refrain that high drug prices are justified because drug development costs billions, while true, no longer moves the needle in the debate.
Read the full article: How pharma cos can shape the drug-pricing landscape
Publication
On 29 November 2024, the first tranche of sweeping Australian privacy reforms under the Privacy and Other Legislation Amendment Bill 2024 (Cth) (Bill) passed both Houses of Parliament.
Publication
A value-referenced crypto asset (VRCA, commonly known as a “stablecoin”) is a crypto asset designed to maintain a stable value over time by referencing the value of a fiat currency, such as the US dollar, or any other value or right, or a combination thereof. It can be used as a medium of exchange or as a store of value that is less volatile than other crypto assets.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023
